Literature DB >> 18081705

Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates.

Naseema Gangat1, Jacob Strand, Terra L Lasho, Christy M Finke, Ryan A Knudson, Animesh Pardanani, Chin-Yang Li, Rhett P Ketterling, Ayalew Tefferi.   

Abstract

The prognostic significance of cytogenetic findings at diagnosis in polycythemia vera (PV) was investigated in a retrospective series of 137 patients. Cytogenetics were normal in 117 patients (85%) and displayed a -Y abnormality in five patients (7% of male patients), and other chromosomal abnormalities in 15 patients (11%). The most frequent cytogenetic anomalies were trisomy 8 (n = 4), trisomy 9 (n = 2), deletion 20q (n = 2) and chromosomal 1 abnormalities (n = 2). Parameters that were significantly associated with abnormal cytogenetics included age > or = 60 yr (P = 0.02), but not JAK2V617F allele burden, thrombosis, hemorrhage, leukemic/fibrotic transformation, or survival. We conclude that cytogenetic anomalies occur infrequently at PV diagnosis and do not confer an adverse outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081705     DOI: 10.1111/j.1600-0609.2007.01003.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  18 in total

1.  Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon.

Authors:  Władysław B Gaweł; Grzegorz Helbig; Kinga Boral; Sławomira Kyrcz-Krzemień
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-24       Impact factor: 0.900

2.  A case of myelodysplastic syndrome with a der(1;18)(q10;q10) translocation.

Authors:  Jung-Sook Ha; Dong-Suk Jeon
Journal:  Blood Res       Date:  2014-06-25

3.  Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.

Authors:  Emil Kuriakose; Katherine Vandris; Y Lynn Wang; William Chow; Amy V Jones; Paul Christos; Nicholas C P Cross; Richard T Silver
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

4.  New and old prognostic factors in polycythemia vera.

Authors:  Francesco Passamonti
Journal:  Curr Hematol Malig Rep       Date:  2009-01       Impact factor: 3.952

5.  Significance of cytogenetic abnormalities in patients with polycythemia vera.

Authors:  Matjaz Sever; Alfonso Quintás-Cardama; Sherry Pierce; Lingsha Zhou; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-04-17

6.  Two clinical phenotypes in polycythemia vera.

Authors:  Jerry L Spivak; Michael Considine; Donna M Williams; Conover C Talbot; Ophelia Rogers; Alison R Moliterno; Chunfa Jie; Michael F Ochs
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

Review 7.  Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.

Authors:  Ayalew Tefferi; Radek Skoda; James W Vardiman
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

Review 8.  Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis.

Authors:  Nisha R Singh
Journal:  Transl Pediatr       Date:  2015-04

Review 9.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

10.  Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.

Authors:  Leonardo Caires Dos Santos; Juliana Corrêa da Costa Ribeiro; Neusa Pereira Silva; Janete Cerutti; Maria Regina Regis da Silva; Maria de Lourdes Lopes Ferrari Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.